

Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among insured adults in the United States during 2024–2025: a retrospective matched cohort study

Amanda Wilson¹, Ekkehard Beck¹, Heather R Hensler¹, Nevena Vicic¹, Keya Joshi¹, Emily Patry¹, Linwei Li¹, Jane Wang¹, Chris Clarke¹

Affiliations:

1. Moderna, Inc

Corresponding author: Amanda Wilson, Moderna, 325 Binney St., Cambridge MA 02142.
amanda.wilson@modernatx.com

Supplemental Table 1. Censoring Reasons

	mRNA-1273	NVX-CoV2705
Medically-attended COVID-19		
Another COVID-19 vaccination reported	664 (0.96%)	462 (1.34%)
Death	600 (0.87%)	277 (0.80%)
Early infection (<day 7)	25 (0.04%)	23 (0.07%)
End of study	58743 (84.96%)	29206 (84.48%)
Event within follow-up period	706 (1.02%)	512 (1.48%)
Loss of enrollment	8402 (12.15%)	4090 (11.83%)
Hospitalization with COVID-19		
Another COVID-19 vaccination reported	677 (0.98%)	471 (1.36%)
Death	603 (0.87%)	279 (0.81%)
Early infection (<day 7)	25 (0.04%)	23 (0.07%)
End of study	59334 (85.82%)	29625 (85.70%)
Event within follow-up period	61 (0.09%)	49 (0.14%)
Loss of enrollment	8440 (12.21%)	4123 (11.93%)